Page 29 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 16 of 16 Guideline

27. Lo Re V, 3rd, Carbonari DM, Lewis JD, et al. Oral Azole antifungal medications and 47. Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul S. Effect
risk of acute liver injury, overall and by chronic liver disease status. Am J Med. of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS.
2016;129(3):283–291. https://doi.org/10.1016/j.amjmed.2015.10.029 Clin Pharmacokinet. 2004;43(11):725–732. https://doi.org/10.2165/00003088-
28. Britz E, Perovic O, von Mollendorf C, et al. The epidemiology of meningitis among 200443110-00003
adults in a South African province with a high HIV prevalence, 2009–2012. PLoS 48. Meiring S, Fortuin-de Smidt M, Kularatne R, Dawood H, Govender NP, Germs SA.
One. 2016;11(9):e0163036. https://doi.org/10.1371/journal.pone.0163036 Prevalence and hospital management of amphotericin B deoxycholate-related
29. McCarthy KM, Morgan J, Wannemuehler KA, et al. Population-based surveillance toxicities during treatment of HIV-associated cryptococcal meningitis in South
Africa. PLoS Negl Trop Dis. 2016;10(7):e0004865. https://doi.org/10.1371/
for cryptococcosis in an antiretroviral-naive South African province with a high journal.pntd.0004865
HIV seroprevalence. AIDS. 2006;20(17):2199–2206. https://doi.org/10.1097/
QAD.0b013e3280106d6a 49. Bicanic T, Bottomley C, Loyse A, et al. Toxicity of amphotericin B deoxycholate-
30. Jarvis JN, Meintjes G, Williams Z, Rebe K, Harrison TS. Symptomatic relapse of HIV- based induction therapy in patients with HIV-associated cryptococcal meningitis.
Antimicrob Agents Chemother. 2015;59(12):7224–7231. https://doi.org/10.1128/
associated cryptococcal meningitis in South Africa: The role of inadequate secondary AAC.01698-15
prophylaxis. S Afr Med J. 2010;100(6):378–382. https://doi.org/10.7196/SAMJ.3515 50. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis
31. Kwizera R, Akampurira A, Williams D, Boulware DR, Meya DB, Team A-CS. Acridine with combination amphotericin B and flucytosine for four as compared with
orange fluorescent microscopy is more sensitive than India ink light microscopy six weeks. N Engl J Med. 1987;317(6):334–341. https://doi.org/10.1056/
in the rapid detection of cryptococcosis among CrAg positive HIV patients. PLoS NEJM198708063170602
One. 2017;12(7):e0182108. https://doi.org/10.1371/journal.pone.0182108 51. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B
32. Meya DB, Kiragga AN, Nalintya E, et al. Reflexive laboratory-based cryptococcal plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann
antigen screening and preemptive fluconazole therapy for cryptococcal Intern Med. 1990;113(3):183–187. https://doi.org/10.7326/0003-4819-113-
antigenemia in HIV-infected individuals with CD4 <100 cells/microL: A stepped- 3-183
wedge, cluster-randomized trial. J Acquir Immune Defic Syndr. 2019;80(2):182–
189. https://doi.org/10.1097/QAI.0000000000001894 52. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole
and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin
33. Morgan J, McCarthy KM, Gould S, et al. Cryptococcus gattii infection: Infect Dis. 1998;26(6):1362–1366. https://doi.org/10.1086/516372
Characteristics and epidemiology of cases identified in a South African province
with high HIV seroprevalence, 2002-2004. Clin Infect Dis. 2006;43(8):1077–1080. 53. Brouwer AE, van Kan HJ, Johnson E, et al. Oral versus intravenous flucytosine in
https://doi.org/10.1086/507897 patients with human immunodeficiency virus-associated cryptococcal meningitis.
Antimicrob Agents Chemother. 2007;51(3):1038–1042. https://doi.org/10.1128/
34. Williams DA, Kiiza T, Kwizera R, et al. Evaluation of fingerstick cryptococcal antigen AAC.01188-06
lateral flow assay in HIV-infected persons: A diagnostic accuracy study. Clin Infect
Dis. 2015;61(3):464–467. https://doi.org/10.1093/cid/civ263 54. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: A review of its pharmacology,
clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob
35. Govender NP, Patel J, van Wyk M, et al. Trends in antifungal drug susceptibility Chemother. 2000;46(2):171–179. https://doi.org/10.1093/jac/46.2.171
of Cryptococcus neoformans isolates obtained through population-based 55. Theron E. Development of a tool to ensure correct stock management and
surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents accurate administration of intravenous amphotericin B. S Afr Pharmaceut J.
Chemother. 2011;55(6):2606–2611. https://doi.org/10.1128/AAC.00048-11 2009:40–42.
36. Pullen MF, Kakooza F, Nalintya E, et al. Change in plasma CrAg titer is not
associated with survival among HIV-infected persons receiving preemptive 56. Rajasingham R, Williams D, Meya DB, Meintjes G, Boulware DR, Scriven J. Nosocomial
therapy for asymptomatic cryptococcal antigenemia. Clin Infect Dis. 2019;May 22. drug-resistant bacteremia in 2 cohorts with cryptococcal meningitis, Africa. Emerg
pii: ciz418. https://doi.org/10.1093/cid/ciz418 Infect Dis. 2014;20(4):722–724. https://doi.org/10.3201/eid2004.131277
57. Musubire AK, Meya DB, Rhein J, et al. Blood neutrophil counts in HIV-
37. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal infected patients with cryptococcal meningitis: Association with mortality.
antigen in serum and cerebrospinal fluid: Value in the management of AIDS- PLoS One. 2018;13(12):e0209337. https://doi.org/10.1371/journal.pone.
associated cryptococcal meningitis. Clin Infect Dis. 1994;18(5):789–792. https:// 0209337
doi.org/10.1093/clinids/18.5.789
38. Smith KD, Achan B, Hullsiek KH, et al. Increased antifungal drug resistance in 58. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of
antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis
clinical isolates of Cryptococcus neoformans in Uganda. Antimicrob Agents in sub-Saharan Africa. Clin Infect Dis. 2010;50(11):1532–1538. https://doi.
Chemother. 2015;59(12):7197–7204. https://doi.org/10.1128/AAC.01299-15 org/10.1086/652652
39. Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, et al. Cryptococcus 59. Boulware DR, Meya DB. Antiretroviral therapy after cryptococcal meningitis. N
neoformans-Cryptococcus gattii species complex: An international study of wild- Engl J Med. 2014;371(12):1166–1167. https://doi.org/10.1056/NEJMc1409052
type susceptibility endpoint distributions and epidemiological cutoff values for
amphotericin B and flucytosine. Antimicrob Agents Chemother. 2012;56(6):3107– 60. Bisson GP, Molefi M, Bellamy S, et al. Early versus delayed antiretroviral therapy
3113. https://doi.org/10.1128/AAC.06252-11 and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal
40. Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clin meningitis. Clin Infect Dis. 2013;56(8):1165–1173. https://doi.org/10.1093/cid/
cit019
Infect Dis. 1998;27(2):260–264. https://doi.org/10.1086/514669
41. Loyse A, Dromer F, Day J, Lortholary O, Harrison TS. Flucytosine and cryptococcosis: 61. Loyse A, Wainwright H, Jarvis JN, et al. Histopathology of the arachnoid
granulations and brain in HIV-associated cryptococcal meningitis: Correlation with
Time to urgently address the worldwide accessibility of a 50-year-old antifungal. J cerebrospinal fluid pressure. AIDS. 2010;24(3):405–410. https://doi.org/10.1097/
Antimicrob Chemother. 2013;68(11):2435–2444. https://doi.org/10.1093/jac/dkt221 QAD.0b013e328333c005
42. Loyse A, Burry J, Cohn J, et al. Leave no one behind: Response to new evidence 62. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased
and guidelines for the management of cryptococcal meningitis in low-income and intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID
middle-income countries. Lancet Infect Dis. 2019;19(4):e143–e147. https://doi. Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis.
org/10.1016/S1473-3099(18)30493-6 2000;30(1):47–54. https://doi.org/10.1086/313603
43. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose 63. Boyles TH, Gatley E, Wasserman S, Meintjes G. Brief report: Flow rate
fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. of cerebrospinal fluid through a spinal needle can accurately predict
Clin Infect Dis. 2008;47(12):1556–1561. https://doi.org/10.1086/ 593194 intracranial pressure in cryptococcal meningitis. J Acquir Immune Defic Syndr.
44. Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with 2017;74(3):e64–e6. https://doi.org/10.1097/QAI.0000000000001183
flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med 64. Mogambery TA, Moodley A, Connolly C. Is the intravenous giving set a reliable
Mycol. 2008;46(4):393–395. https://doi.org/10.1080/13693780701851695 alternative to the spinal manometer in measuring cerebrospinal fluid opening
45. Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal pressure? S Afr Med J. 2018;108(10):865–869. https://doi.org/10.7196/
amphotericin B and conventional amphotericin B deoxycholate for treatment SAMJ.2018.v108i10.13176
of AIDS-associated acute cryptococcal meningitis: A randomized, double-blind 65. Vidal JE, Peixoto de Miranda EJ, Gerhardt J, Croda M, Boulware DR. Is it possible
clinical trial of efficacy and safety. Clin Infect Dis. 2010;51(2):225–232. https://doi. to differentiate tuberculous and cryptococcal meningitis in HIV-infected
org/10.1086/653606 patients using only clinical and basic cerebrospinal fluid characteristics? S
46. Gilead. Gilead Sciences announces steep discounts for ambisome to treat Afr Med J. 2017;107(2):156–159. https://doi.org/10.7196/SAMJ.2017.v107i2.
11162
cryptococcal meningitis in low- and middle-income countries [homepage on
the Internet]. Gilead; 2018 [updated 07 September 2018; cited]. Available from: 66. Ellis J, Cresswell FV, Rhein J, Ssebambulidde K, Boulware DR. Cryptococcal meningitis
https://www.gilead.com/news-and-press/company-statements/discount-for- and tuberculous meningitis co-infection in HIV-infected Ugandan adults. Open
ambisome. Forum Infect Dis. 2018;5(8):ofy193. https://doi.org/10.1093/ofid/ofy193

http://www.sajhivmed.org.za 22 Open Access